Shares of Vital Therapies, Inc. (NASDAQ:VTL) have earned a consensus rating of “Hold” from the six research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $8.00.

Several research analysts have commented on VTL shares. BidaskClub raised shares of Vital Therapies from a “buy” rating to a “strong-buy” rating in a report on Thursday. Zacks Investment Research downgraded shares of Vital Therapies from a “hold” rating to a “sell” rating in a report on Thursday.

ILLEGAL ACTIVITY WARNING: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/05/vital-therapies-inc-vtl-receives-consensus-rating-of-hold-from-brokerages.html.

Shares of Vital Therapies (NASDAQ:VTL) traded up 5.22% on Thursday, reaching $6.05. 127,883 shares of the company’s stock traded hands. Vital Therapies has a one year low of $2.25 and a one year high of $6.58. The company’s 50-day moving average price is $3.90 and its 200 day moving average price is $3.41. The firm’s market cap is $255.35 million.

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. During the same quarter in the prior year, the company earned ($0.30) earnings per share. On average, equities analysts forecast that Vital Therapies will post ($1.31) EPS for the current fiscal year.

In other Vital Therapies news, Director Muneer A. Satter bought 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were bought at an average price of $3.53 per share, for a total transaction of $176,500.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Muneer A. Satter bought 130,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was acquired at an average price of $4.01 per share, for a total transaction of $521,300.00. The disclosure for this purchase can be found here. Insiders have bought a total of 190,000 shares of company stock valued at $737,800 over the last ninety days. 32.60% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. Susquehanna International Group LLP purchased a new position in Vital Therapies in the 2nd quarter worth $268,000. Goldman Sachs Group Inc. raised its position in Vital Therapies by 261.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock worth $676,000 after purchasing an additional 168,705 shares during the period. Victory Capital Management Inc. raised its position in Vital Therapies by 1.2% in the 2nd quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock worth $7,480,000 after purchasing an additional 29,840 shares during the period. Blair William & Co. IL raised its position in Vital Therapies by 67.2% in the 2nd quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock worth $289,000 after purchasing an additional 40,000 shares during the period. Finally, LMR Partners LLP purchased a new position in Vital Therapies in the 2nd quarter worth $396,000. Institutional investors own 25.58% of the company’s stock.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.